2m 2m 2m 2m 2m 2m 2m
OS THERAP (OSTX)
NYSE
$1.82+$0.02 (+1.11%)
Price as of Jun 03, 2026 7:57 PM EDT- $95.3MMarket Cap
- 15.09%1-Year Change
- BiotechnologyIndustry
OS THERAP (OSTX)
$1.82+$0.02 (+1.11%)
Annual
Quarterly
12/31/2025 | 12/31/2024 | ||
|---|---|---|---|
Income Statement | |||
Total Operating Revenue | N/A N/A | N/A N/A | |
Cost of Revenue | N/A N/A | N/A N/A | |
Gross Profit | 0 N/A | 0 N/A | |
Sales and Marketing Expense | N/A N/A | N/A N/A | |
Research and Development Expense | -16.4M +476.27% | -2.8M N/A | |
Depreciation and Amortization Expense | 363,085 +12,960.61% | 2,780 N/A | |
Total Operating Expenses | 12.3M +210.58% | 4.0M N/A | |
Operating Profit | -28.7M +321.28% | -6.8M N/A | |
Interest Income | 249 -99.27% | 33,997 N/A | |
Interest Expense | N/A N/A | -2.1M N/A | |
Interest Income and Expense and Net | 249 +100.01% | -2.0M N/A | |
Total Nonoperating Income and Expense | -48,143 -97.67% | -2.1M N/A | |
Income before Taxes | -28.8M +164.13% | -10.9M N/A | |
Income Taxes | N/A N/A | N/A N/A | |
Extraordinary Items | N/A N/A | N/A N/A | |
Net Income | -28.8M +223.70% | -8.9M N/A | |
Net Income from Continuing Operations Applicable to Common | -28.8M +164.13% | -10.9M N/A | |
Basic EPS and Net Income | -0.98 +11.36% | -0.88 N/A | |
Diluted EPS and Net Income | -0.98 +11.36% | -0.88 N/A | |
Basic Weighted Average Shares | 29.3M +136.35% | 12.4M N/A | |
Diluted Weighted Average Shares | 29.3M +136.35% | 12.4M N/A | |
Balance Sheet | |||
Cash and Cash Equivalents | 269,830 -95.12% | 5.5M N/A | |
Short-Term Investments | N/A N/A | N/A N/A | |
Cash and Cash Equivalents and Short-Term Investments | 269,830 -95.12% | 5.5M N/A | |
Total Current Assets | 332,912 -93.98% | 5.5M N/A | |
Accumulated Depreciation | N/A N/A | N/A N/A | |
Property and Plant and Equipment and Net | 2,490 -52.75% | 5,270 N/A | |
Total Long-Term Assets | 6.5M +123,365.31% | 5,270 N/A | |
Total Assets | 6.8M +23.48% | 5.5M N/A | |
Income Taxes Payable | N/A N/A | N/A N/A | |
Total Short-Term Debt | 150,000 0.00% | 150,000 N/A | |
Total Current Liabilities | 11.8M +154.24% | 4.6M N/A | |
Total Long-Term Debt | 0 N/A | 0 N/A | |
Total Long-Term Liabilities | 100,000 0.00% | 100,000 N/A | |
Total Liabilities | 11.9M +150.98% | 4.7M N/A | |
Retained Earnings | -67.2M +66.28% | -40.4M N/A | |
Total Stockholders Equity | -6.1M +16.36% | -5.2M N/A | |
Total Shares Outstanding | 37.1M +77.83% | 20.9M N/A | |
Cash Flow | |||
Cash from Operating Activities | -14.2M +95.52% | -7.3M N/A | |
Capital Expenditures | 466,423 N/A | N/A N/A | |
Cash from Investing Activities | -466,423 N/A | N/A N/A | |
Dividends Paid | N/A N/A | N/A N/A | |
Cash from Financing Activities | 9.4M -26.11% | 12.8M N/A | |
Financials Ratio | |||
Gross Margin | N/A N/A | N/A N/A | |
Operating Margin | N/A N/A | N/A N/A | |
Return on Assets | -464.58% N/A | N/A N/A | |
Return on Equity | 507.38% N/A | N/A N/A | |
Revenue Growth | N/A N/A | N/A N/A | |
Current Ratio | 0.03 N/A | N/A N/A | |
Cash Ratio | 0.02 N/A | N/A N/A | |
Debt-to-Equity Ratio | -0.02 N/A | N/A N/A | |
Debt-to-Assets Ratio | 0.02 N/A | N/A N/A | |
Earnings & Revenue History
Debt-to-Assets
Cash Flow